Cite

    Heiblig, M. et al. (2020). Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. Expert review of precision medicine and drug development. 5 (6), pp. 421-428. [Online].